<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927927</url>
  </required_header>
  <id_info>
    <org_study_id>NN8555-3618</org_study_id>
    <secondary_id>2008-008703-18</secondary_id>
    <nct_id>NCT00927927</nct_id>
  </id_info>
  <brief_title>First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to investigate the
      safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and
      signs of clinical efficacy of increasing single doses or four repeated doses of NNC 0142-0002
      in patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.</time_frame>
    <description>Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC)</measure>
    <time_frame>Data were collected from 0 hours to at least Day 43 (SD cohorts) and Day 85 (MD cohorts), and until the receptor occupancy was confirmed below the cut-off level for receptor positivity.</time_frame>
    <description>Systemic exposure to NNC0142-0002.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SD 0.0002 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 0.0012 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 0.007 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 0.035 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 0.175 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 0.7 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 2.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD 7.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected once with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD 0.02 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD 0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD 1.6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD 4.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MD Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were injected biweekly four times with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.0002 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.0012 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.007 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.035 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.175 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 0.7 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 2.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1</description>
    <arm_group_label>SD 7.5 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times</description>
    <arm_group_label>SD Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly</description>
    <arm_group_label>MD 0.02 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly</description>
    <arm_group_label>MD 0.3 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly</description>
    <arm_group_label>MD 1.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly</description>
    <arm_group_label>MD 1.6 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0142-0002</intervention_name>
    <description>Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly</description>
    <arm_group_label>MD 4.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times</description>
    <arm_group_label>MD Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active rheumatoid arthritis, characterized by a Disease Activity Score (DAS28) above
             3.2, and a diagnosis of at least three months duration

          -  Aged between 18 and 75 years (both inclusive)

          -  Subjects on stable doses of methotrexate for at least 4 weeks prior to dosing

          -  Use of highly effective contraception during the trial (both males and females)

        Exclusion Criteria:

          -  A chronic inflammatory autoimmune or joint disease other than RA (rheumatoid
             arthritis)

          -  An active or latent tuberculosis

          -  Any investigational or experimental therapy within 4 weeks or 5 half-lives (whichever
             is longer) prior to the screening visit

          -  A known significant cardio-vascular disease

          -  Vaccination against live virus or bacteria within 4 weeks prior to randomization

          -  The use of concomitant medications that are prohibited in the trial (e.g., certain
             DMARDs (antirheumatic therapies that are disease modifying), biologics (here:
             biotechnologically produced antibodies), intra-articular corticoid-injections, etc.)

          -  A positive test result for human immunodeficiency virus (HIV) infection, hepatitis B
             and/or hepatitis C, or tuberculosis skin test

          -  Donation of greater than or equal to 400 ml of blood within 8 weeks prior to trial
             entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britta Væver Bysted, DVM, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>April 25, 2013</results_first_submitted>
  <results_first_submitted_qc>October 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2013</results_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at one site in Germany.</recruitment_details>
      <pre_assignment_details>A total of 65 subjects were randomised, but only 64 subjects were exposed to trial product. One subject withdrew consent after being randomised but before receiving any trial product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SD 0.0002 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>SD 0.0012 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>SD 0.007 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>SD 0.035 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
        </group>
        <group group_id="P5">
          <title>SD 0.175 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
        </group>
        <group group_id="P6">
          <title>SD 0.7 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
        </group>
        <group group_id="P7">
          <title>SD 2.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
        </group>
        <group group_id="P8">
          <title>SD 7.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
        </group>
        <group group_id="P9">
          <title>SD Placebo</title>
          <description>Subjects were dosed once with placebo</description>
        </group>
        <group group_id="P10">
          <title>MD 0.02 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
        </group>
        <group group_id="P11">
          <title>MD 0.3 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
        </group>
        <group group_id="P12">
          <title>MD 1.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
        </group>
        <group group_id="P13">
          <title>MD 1.6 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
        </group>
        <group group_id="P14">
          <title>MD 4.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
        </group>
        <group group_id="P15">
          <title>MD Placebo</title>
          <description>Subjects were injected biweekly four times with placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="4">One subject withdrew consent after being randomised but before receiving any trial product.</participants>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SD 0.0002 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>SD 0.0012 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>SD 0.007 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>SD 0.035 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
        </group>
        <group group_id="B5">
          <title>SD 0.175 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
        </group>
        <group group_id="B6">
          <title>SD 0.7 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
        </group>
        <group group_id="B7">
          <title>SD 2.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
        </group>
        <group group_id="B8">
          <title>SD 7.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
        </group>
        <group group_id="B9">
          <title>SD Placebo</title>
          <description>Subjects were dosed once with placebo</description>
        </group>
        <group group_id="B10">
          <title>MD 0.02 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
        </group>
        <group group_id="B11">
          <title>MD 0.3 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
        </group>
        <group group_id="B12">
          <title>MD 1.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
        </group>
        <group group_id="B13">
          <title>MD 1.6 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
        </group>
        <group group_id="B14">
          <title>MD 4.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
        </group>
        <group group_id="B15">
          <title>MD Placebo</title>
          <description>Subjects were injected biweekly four times with placebo</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="3"/>
            <count group_id="B11" value="5"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="5"/>
            <count group_id="B14" value="5"/>
            <count group_id="B15" value="9"/>
            <count group_id="B16" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="7.9"/>
                    <measurement group_id="B2" value="60.7" spread="8.1"/>
                    <measurement group_id="B3" value="66.7" spread="8.1"/>
                    <measurement group_id="B4" value="58.3" spread="5.1"/>
                    <measurement group_id="B5" value="58.7" spread="3.1"/>
                    <measurement group_id="B6" value="52.7" spread="11.0"/>
                    <measurement group_id="B7" value="49.0" spread="10.8"/>
                    <measurement group_id="B8" value="69.0" spread="4.6"/>
                    <measurement group_id="B9" value="52.8" spread="7.8"/>
                    <measurement group_id="B10" value="55.3" spread="5.0"/>
                    <measurement group_id="B11" value="56.4" spread="9.4"/>
                    <measurement group_id="B12" value="58.4" spread="5.5"/>
                    <measurement group_id="B13" value="53.0" spread="17.9"/>
                    <measurement group_id="B14" value="48.2" spread="7.7"/>
                    <measurement group_id="B15" value="53.7" spread="11.0"/>
                    <measurement group_id="B16" value="56.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Adverse Events</title>
        <description>Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.</description>
        <time_frame>Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.</time_frame>
        <population>All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>SD 0.0002 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SD 0.0012 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>SD 0.007 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>SD 0.035 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>SD 0.175 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>SD 0.7 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
          </group>
          <group group_id="O7">
            <title>SD 2.5 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
          </group>
          <group group_id="O8">
            <title>SD 7.5 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
          </group>
          <group group_id="O9">
            <title>SD Placebo</title>
            <description>Subjects were dosed once with placebo</description>
          </group>
          <group group_id="O10">
            <title>MD 0.02 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
          </group>
          <group group_id="O11">
            <title>MD 0.3 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
          </group>
          <group group_id="O12">
            <title>MD 1.0 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
          </group>
          <group group_id="O13">
            <title>MD 1.6 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
          </group>
          <group group_id="O14">
            <title>MD 4.0 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
          </group>
          <group group_id="O15">
            <title>MD Placebo</title>
            <description>Subjects were injected biweekly four times with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events</title>
          <description>Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.</description>
          <population>All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="13"/>
                    <measurement group_id="O13" value="10"/>
                    <measurement group_id="O14" value="14"/>
                    <measurement group_id="O15" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC)</title>
        <description>Systemic exposure to NNC0142-0002.</description>
        <time_frame>Data were collected from 0 hours to at least Day 43 (SD cohorts) and Day 85 (MD cohorts), and until the receptor occupancy was confirmed below the cut-off level for receptor positivity.</time_frame>
        <population>All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo. Serum drug concentrations after dosing with less than 0.175 mg/kg (SD cohorts) and 0.3 mg/kg (MD cohorts) were below the lower limit of quantification.</population>
        <group_list>
          <group group_id="O1">
            <title>SD 0.0002 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>SD 0.0012 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>SD 0.007 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>SD 0.035 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
          </group>
          <group group_id="O5">
            <title>SD 0.175 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
          </group>
          <group group_id="O6">
            <title>SD 0.7 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
          </group>
          <group group_id="O7">
            <title>SD 2.5 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
          </group>
          <group group_id="O8">
            <title>SD 7.5 mg/kg</title>
            <description>Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
          </group>
          <group group_id="O9">
            <title>SD Placebo</title>
            <description>Subjects were dosed once with placebo</description>
          </group>
          <group group_id="O10">
            <title>MD 0.02 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
          </group>
          <group group_id="O11">
            <title>MD 0.3 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
          </group>
          <group group_id="O12">
            <title>MD 1.0 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
          </group>
          <group group_id="O13">
            <title>MD 1.6 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
          </group>
          <group group_id="O14">
            <title>MD 4.0 mg/kg</title>
            <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
          </group>
          <group group_id="O15">
            <title>MD Placebo</title>
            <description>Subjects were injected biweekly four times with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC)</title>
          <description>Systemic exposure to NNC0142-0002.</description>
          <population>All randomised subjects exposed to at least one dose of NNC0142-0002 or placebo. Serum drug concentrations after dosing with less than 0.175 mg/kg (SD cohorts) and 0.3 mg/kg (MD cohorts) were below the lower limit of quantification.</population>
          <units>microgram×h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Exposure was below lower level of quantification.</measurement>
                    <measurement group_id="O2" value="NA">Exposure was below lower level of quantification.</measurement>
                    <measurement group_id="O3" value="NA">Exposure was below lower level of quantification.</measurement>
                    <measurement group_id="O4" value="NA">Exposure was below lower level of quantification.</measurement>
                    <measurement group_id="O5" value="91" spread="306.6" lower_limit="306.6"/>
                    <measurement group_id="O6" value="4229" spread="12.7" lower_limit="12.7"/>
                    <measurement group_id="O7" value="16616" spread="35.2" lower_limit="35.2"/>
                    <measurement group_id="O8" value="87461" spread="29.9" lower_limit="29.9"/>
                    <measurement group_id="O9" value="NA">AUC was not calculated as subjects were not exposed to NNC0142-0002.</measurement>
                    <measurement group_id="O10" value="NA">Exposure was below lower level of quantification.</measurement>
                    <measurement group_id="O11" value="4034" spread="62.8" lower_limit="62.8"/>
                    <measurement group_id="O12" value="21883" spread="29.6" lower_limit="29.6"/>
                    <measurement group_id="O13" value="30212" spread="25.4" lower_limit="25.4"/>
                    <measurement group_id="O14" value="83307" spread="38.3" lower_limit="38.3"/>
                    <measurement group_id="O15" value="NA">AUC was not calculated as subjects were not exposed to NNC0142-0002.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.</time_frame>
      <desc>The safety analysis set included all randomised subjects exposed to at least one dose of NNC0142-0002 or placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>SD 0.0002 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0002 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>MD 0.02 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>SD 0.0012 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.0012 mg/kg</description>
        </group>
        <group group_id="E4">
          <title>SD 0.007 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.007 mg/kg</description>
        </group>
        <group group_id="E5">
          <title>SD 0.035 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.035 mg/kg</description>
        </group>
        <group group_id="E6">
          <title>SD 0.175 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.175 mg/kg</description>
        </group>
        <group group_id="E7">
          <title>SD 0.7 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 0.7 mg/kg</description>
        </group>
        <group group_id="E8">
          <title>SD 2.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 2.5 mg/kg</description>
        </group>
        <group group_id="E9">
          <title>SD 7.5 mg/kg</title>
          <description>Subjects were dosed once with NNC0142-0002 at a dose of 7.5 mg/kg</description>
        </group>
        <group group_id="E10">
          <title>SD Placebo</title>
          <description>Subjects were dosed once with placebo</description>
        </group>
        <group group_id="E11">
          <title>MD 0.3 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg</description>
        </group>
        <group group_id="E12">
          <title>MD 1.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg</description>
        </group>
        <group group_id="E13">
          <title>MD 1.6 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg</description>
        </group>
        <group group_id="E14">
          <title>MD 4.0 mg/kg</title>
          <description>Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg</description>
        </group>
        <group group_id="E15">
          <title>MD Placebo</title>
          <description>Subjects were injected biweekly four times with placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E12" events="5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E13" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incorrect dose administered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus antibody positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right to defer data release until specified milestones, e.g. availability of a clinical trial report. Novo Nordisk reserves the right to postpone publication and/or communication for short period to protect intellectual property. Novo Nordisk reserves the right to prior review of site-specific publications and to ask for deferment of publication of individual site results until after the primary manuscript is accepted for publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Maximum tolerated dose was not reached.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>RA-RNDUS-ClinTriDisc@ITS.JNJ.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

